Scieists have discovered a drug that can stop and reverse the deadly liver fibrosis. They have ideified the HDAC3 enzyme as a promising goal in the treatme of sile but fatal liver fibrosis.
According to RCO News AgencyLiver fibrosis often develops without symptoms and has no approved treatme, but researchers at the University of Sunderland have discovered a new enzyme blocker treatme that can ultimately help stop or reverse the disease.
Fibrosis, or “fiber corruption”, is the disease of the swelling of the filameous tissue, and the hardening of connective tissue, which results in the increase in the formation of fibers in the connective tissue during a recovery or irreversible process. Fibrosis may be benign, maligna or pathogenic.
According to IA, Dr. Maria Teresa Borrelo and his team found that blocking an enzyme called “HDAC1” with new developed drugs could reduce liver ulcers in people with fibrosis.
The “HDAC1” enzyme is involved in regulating inflammation and cellular stress, and research shows that the activation of liver star cells responsible for collagen production (the main tissue stimula).
Blocking damage in source
Dr. Borllo, a lecturer in pharmaceutical chemistry at the University of Sunderland, said his team has developed two new drugs designed specifically to preve HDAC1 activity.
“We have so far seen a encouraging laboratory that shows that inhibitors or” HDAC1 “inhibitors or blockers are reducing inflammation and cellular stress responses, both of which are key fibrosis factors,” he said.
“The findings support the idea that” HDAC1 “is a promising drug goal for the treatme of liver fibrosis,” he said. We have also begun to understand more about how these compounds work at the molecular level, which is esseial to designing better and safer treatmes.
The researchers hope that their findings will be the basis for new treatmes that can significaly improve the lives of people with the disease and other inflammatory diseases, including skin disorders.
“The study is a step forward in finding a treatme for” liver fibrosis “,” says Dr. Borlo. Our HDAC3 inhibitors provide a more targeted approach, and by focusing on a main cause of the fibrosis, we may be able to stop the disease before reaching irreversible stages.
By stopping or reverseing this process, we can reduce the need for liver transplaation and improve long -term health results.
From the laboratory to the liver
Researchers believe that targeting the main cause of fibrosis can be a turning poi in the treatme of liver disease.
As efforts to couer chronic conditions, such accurate treatmes can change how to manage ureatable diseases.
The British Liver Liver Charity has welcomed the findings of the study.
“Liver disease is often without symptoms, and most people only realize that it is too late for effective treatme,” says Pamela Healy. While this new study is still in its early stages, it is a promise of therapeutic developme that can improve and save the lives of thousands of liver disease.
Liver disease is responsible for about four perce of the world’s premature deaths, with “liver fibrosis” one of the most serious and often unknown forms.
In the United Kingdom only, about 5 million people have the disease. This condition occurs when prolonged damage to the liver, which is usually caused by alcohol, obesity, or chronic infections, causes tissue to form.
As the wound worsen over time, it can lead to life -threatening complications such as liver failure or cancer.
Since its symptoms often appear only in advanced stages, many people are unaware of the disease, and there are currely no approved treatme to stop or reverse this process.
This study is published in The FBS journal.
The end of the message
(tagstotranslate) Liver fibrosis (T) enzyme (T) liver cancer
